The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. by Cote, R. J. et al.
Britsh Joumal of Cancer (1998) 78 3). 413-418
c 1998 Cancer Research Campaign
The effect of finasteride on the prostate gland in men
with elevated serum prostate-specific antigen levels
RJ Cote', EC Skinner2, CE Salem2, SJ Mertes2, FZ Stanczyk4, BE Henderson3, MC Pike3 and RK Ross3
Departments of 'Pathology. 2Urology and 'Preventive Medicine. University of Southem Califomia/Norris Comprehensive Cancer Center: 'Department of
Obstetrics and Gynecology. Women's Hospital. Los Angeles. CA 90033. USA
Summary Prostate cancer is a disease associated with androgens. It has been hypothesized that reducing the conversion of testosterone
(T) to dihydrotestosterone (DHT) in the prostate by the use of the drug finasteride. a 5a-reductase inhibitor, will reduce the incidence of
prostate cancer. We investigated the chemopreventive potential of finasteride by evaluating its effect on the prostate gland of men with
elevated serum prostate-specific antigen (PSA). Fifty-two men with elevated PSA and prostate sextant biopsies negative for cancer were
randomized to receive finastende 5 mg day-, (27 patients) or no medication (25 patients) for 12 months and were rebiopsied at 12 months.
The biopsies were evaluated for the presence of cancer, the proportion of glandular and hyperplastic tissue, and the presence of high-grade
prostatic intraepithelial neoplasia (PIN). Epithelial proliferation was assessed in the prestudy and 12-month biopsies by immuno-
histochemistry using antibody to proliferating cell nuclear antigen (PCNA). Serum blood samples were drawn at baseline and after 1. 3, 6 and
12 months of study. In the control group, serum levels of PSA and T were unchanged throughout the 12 months. In the finastende group, PSA
decreased 48°o (P < 0.001), DHT decreased 670o (P < 0.001) and T increased 210° (P < 0.001). Histological evaluation of prestudy and 12-
month biopsy specimens revealed that the finasteride group had a 300% reduction in the percentage of hyperplastic epithelial tissue
(P = 0.002). although this decrease was not statistically significantly different between the finasteride and control groups (P = 0.11). In
patients with PIN on prestudy biopsy, no change occurred in the PIN lesions with finasterde treatment. Finasteride also had no effect on the
proliferation index of prostatic epithelial cells. Of the 27 patients treated with finastende, eight (309O) had adenocarcinoma of the prostate
detected on the 12-month biopsy. compared with one (40o) of the control patients (P = 0.025). In the treatment group, six cancers occurred in
the eight patients with PIN on the prestudy biopsy: in the observation group no cancers were detected in the five patients with PIN on the
prestudy biopsy (P= 0.021). Two cancers occurred in the 19 men in the treatment group with no evidence of PIN on the prestudy biopsy.
compared with one cancer in the 20 men in the observation group with no evidence of PIN on the prestudy biopsy (P = 0.60). This study, using
a novel model for evaluating short-term efficacy of chemopreventive ortherapeutic agents in men at high nsk of prostate cancer. provides little
evidence that finasteride is an effective chemopreventive agent for prostate cancer in men with elevated PSA.
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Carcinoma of the prostate is the most frequentl diagnosed cancer
in the US. Although the most important risk factor for prostate
cancer is age (Ross et al. 1979). there is also profound -ariation in
incidence between different racial groups in the US. African-
Americans has-e a substantially higher incidence than u-hite
people. w-ho in turn have a substantiallv higher incidence than
Asian-Americans (Ross et al. 1979: Muir et al. 1987). In 1941. the
hormonal dependence of prostate cancer >-as demonstrated
(Huggins and Hodges. 1941). and manv confirmaton- studies
followed (Hovenian and Deming. 1948: Glantz. 1964: Noble.
1977). Based on these observations. we have conducted a series of
epidemiological studies to determine if underling differences in
androgen lexels among men of different racial groups might
explain their Xarxing risk of prostate cancer. Although w-e show-ed
that the level of circulating free testosterone (T) in Xoung
African-American men is higher than in w-hite people (Ross et al.
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1986). T lexels in Asian-Americans are not low. Within the
prostate. T is irrexersibly conx-erted by the type II 5a-reductase
enzyme to dihy-drotestosterone IDHT . a more potent androgen
primariln responsible for prostate growth (Coffey. 1979). DHT is
metabolized intraprostaticallv to androstanediol. which circulates
as a glucuronide conjugate. The serum level of this end metabolite
is substantially lower in Asian-Americans than in w-hite people
(Lookinebill et al. 1991: Ross et al. 19921. We have. therefore.
proposed that the incidence of prostate cancer might be directly
related to the level of Sc-reductase activity.
These and other studies stimulated interest in the use of the Sa-
reductase inhibitor. fmasteride. as a possible chemopreventive agent
for prostate cancer. Treatment w-ith finasteride in men w-ith benign
prostatic hxperplasia (BPH) has been associated with a 17-30%c
reduction in prostate Xolume (averaae 19%k) and a 50% decrease in
circulatinc lexvels ofprostate-specific antigen (PSA (Gormlev et al.
1992: Stoner et al. 1994a: Anderson et al. 1995: Geller. 1995: Lepor
et al. 1996). The short-term side-effects of finasteride treatment
wxere minimal. Based on the hypothesis that 5a-reductase activity is
aetiologicallv important in prostate cancer. the US National Cancer
Institute began a nationwxide trial investigating long-term (7 year)
finasteride treatment as a potential prostate cancerchemopreventive
agent in 18 000healthy adult men.
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Surprisingly little is known about the histological and biological
effects of finasteride on the human prostate. Finasteride reduces
prostate volume more in the central/transitional zone than in the
peripheral zone where most prostate cancers arise (McNeal. 1969:
Tempany et al. 1993). and has a much weaker effect on prostate
epithelial growth in animals than flutamide or leuprolide (Tutrone
et al, 1993). The impact of fmasteride on potential intermnediate
cellular and histopathological markers of prostate cancer risk has
not been investigated.
To address these issues. we randomized a group of men at high
risk for the development of prostate cancer. as evidenced by an
elevated serum PSA (Keetch et al. 1994). either to receive finas-
teride or simply be observed for 12 months. All men had prestudy
prostate sextant peripheral zone biopsies with no evidence of
carcinoma. After 1 year on the study. all men had repeat sextant
biopsies. We examined the effect of finasteride on two candidate
intermediate markers of malignant potential, namely. cellular
proliferation and high-grade prostatic intraepithelial neoplasia
(PIN). If finasteride is useful in the chemoprevention of prostate
cancer, it should result in a decrease in glandular cell proliferation
and possibly a decrease in the incidence and/or severity ofPIN.
METHODS
The study included men age 50 years and older with an elevated
serum PSA (>4.0 ng ml-'). All patients had ultrasound-guided
sextant biopsies negative for cancer before entrance into the study
(prestudy biopsy). Routine follow-up of these patients includes
biannual PSA and annual repeat biopsy. The risk offinding cancer
on repeat biopsy in these men has been estimated to be 15% (in a
selected group of men with persistently elevated PSA) (Keetch et
al, 1994).
Patients were excluded if they had ever been diagnosed with
prostate cancer. had evidence ofsevere or acute chronic prostatitis
or had prior hormone therapy.
Patients were recruited from several institutions. Biopsies from
64 men were confirmed negative for cancer on review (RJC). Six
declined enrolment into the study. A total of 58 men signed an
informed consent and were randomized to treatment (29 patients)
or observation (29 patients). Randomization was accomplished
using aminimization scheme using 5-year age-group strata and two
PSA level strata 4.1 to 9.9 and .10.0 ng ml-' (Pocock and Simon,
1975). Six men did not complete the study for the following
reasons: transurethral resection of prostate (TlURP) performed
during the study (one patient in observation group): decided not to
continue (one patient in each group): started other hormonal
therapy (one patient in observation group): primary physician
declined to authorize follow-up biopsy (one patient in observation
group): and lost to follow-up (one patient in finasteride group).
Fifty-two men completed the study. i.e. underwent a year of
treatment or observation. had serial blood samples drawn and
underwent a sextant biopsy at 12 months (12-month biopsy): 27
were treated with finasteride and 25 were in the observation arm.
Their age range was 57-79 years (average 68 years).
This study was approved by the University of Southern
California School of Medicine Institutional Review Board.
Finasterde treatment
The patients in the treatment group took finasteride 5 mg day-' for
12 months. Serum PSA and hormone levels change consistently
with treatment at this dosage. Compliance was encouraged by
repeated telephone contacts and pill counts at follow-up visits.
Compliance was assessed by measurement of PSA. DHT and T
after 1. 3. 6 and 12 months on study.
Serum evaluations
Serum PSA. DHT and T were measured at enrolment (month 0.
immediately before beginning treatment) and then after at 1. 3. 6
and 12 months. PSA was measured by an enzyme-linked
immunosorbent assay (Hybritech. San Diego. CA. USA). DHT and
T were quantified using validated specific radioimmunoassays in
the University of Southern California Reproductive Endocrine
ResearchLaboratory (FZS). DHTandT were extracted from serum
with hexane-ethyl acetate (1:1) and subjected to celite column
partition chromatography before radioimmunoassay. All assays
were conducted blindly fortreatment status and priorresults.
Protae biopsy
Before enrolment, each patient underwent atransrectal ultrasound-
guided sextant biopsy ofthe prostate: three samples each from the
right and left lobes (proximal. mid anddistal; the prestudy biopsy).
Patients underwent a repeat sextant biopsy at 12 months from
enrolment (the 12-month biopsy); all of the men on finasteride
were actively taking the drug at the time of the 12-month biopsy.
except for one subject who had stopped taking finasteride 2 weeks
before. Each biopsy was fixed in 10% formalin or B5 and
embedded in paraffin. Sections (5jgm) were cut onto individual
slides and stained with haematoxylin and eosin.
Each biopsy slide, both prestudy and 12-month. was reviewed
by the study pathologist (RJC). The pathologist and all persons
involved in tissue processing. was blinded to the patient's random-
ization group and hormone values. The pathologist was also
blinded to the results of any previous histological examination.
The following histological variables were assessed for each slide:
(a) presence ofadenocarcinoma (ifpresent. Gleason grade and per
cent oftissue involved; (b) per cent oftissue that was glandular vs
stroma; (c) per cent of tissue that showed glandular hyperplasia:
(d) presence ofPIN [ifpresenL grade (mild. moderate. severe) and
per cent of tissue involved]. PIN was evaluated using established
criteria (McNeal and Bostwick. 1986). For the purposes of the
analysis, only those patients defined as having high-grade PIN
(moderate and severe, II and HII) were considered positive as only
high-grade PIN is associated with the presence of prostate cancer
(Bostwick and Srigley. 1990; Brawer. 1992). (e) Presence ofacute
or chronic inflammation: if present. grade (mild. moderate.
severe). The results from each of the six sextant specimens were
subsequently averaged in order to derive a single value foreach of
the histological variables.
Prostate epithelial proliferation index
The proliferation rate of the prostate epithelial cells was deter-
mined using antibody to proliferating cell nuclear antigen
(PCNA). PC 10 (Dako. Carpinteria. CA, USA). This antibody is a
common measure of cellular proliferation and can be applied to
formalin- and B5-fixed. paraffin-embedded tissues (Hall et al.
199O: Waseem and Lane. 1990). PCNA is an intranuclear poly-
peptide whose synthesis is maximal during the S-phase ofthe cell
cycle. The imimunohistochemical procedure was carried out using
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Table 1 Effect of finastende on mean serum PSA. DHT and testosterone
levels
Finasteride vs
Variable Finasteride Control control
Number of patients 27 25
PSA (ng ml-)
Baseline 9.18 10.30
12 months 4.74 10.80
Difference -4.44 (-0.87)a 0.50 (+0.64) -4.94 (±1 10)
P < 0.001 P = 0.44 P < 0.001
DHT- (ng dl-)
Baseline 44.7 44.7
12 months 14.7 50.4
Difference- -1.11 (:i0.09) 0.12 (-0.07) -1.23 (t-0.12)
p<0.001 P=0.12 P<0.001
TP (ng dl- )
Baseline 478.2 512.9
12 months 578.2 483.0
Difference; 0.19 (-0.04) -0.06 (+O.04) 0.25 (-0.06)
P<0.001 P=0.12 p<0.001
aValue in parentheses is standard error. :Testosterone and DHT calculations
were made on loganthmtc (base e) scale and exponentiated to give averages
shown. cLogarithmic (base e) scale.
Table 2 Effect of finastende on mean values of pathological parameters
Finasteride vs
Variable Finasteride Control control
Number of patients 27 25
Per cent glandular epitheliuma
Prestudy 37.1 33.8
12 months 35.3 33.7
Difference -1.9 (-1 .8): -0.1 (r-2.1) -1.8 (-2.8)
P= 0.31 P= 0.95 P= 0.53
Per cent hyperplastic epitheliuma
Prestudy 27.7 24.5
12 months 19.4 21.6
Difference -8.3 (-2.3) -2 9 (:2.3) -5.3 (-3.3)
P=0.002 P=0.22 P=0.11
PCNA index:
Number of patients 14 14
Prestudy 0.95 0.67
12 months 1.06 1.03
Difference 0.11 (=0.14) 0.36 (+0.29) -0.26 (i0.32)
P=0.45 P=0.22 P=0.44
aPer cent glandular and hyperplastic epithelium is proportion of the biopsy
occupied by glandular (or hyperplastic) epithelium. "Value in parentheses is
standard error. :PCNA index. number of PCNA-positive epithelial cells per
number of epithelial cells counted in four high-power (400x) fields per biopsy.
the standard ax-idin-biotin-peroxidase technique using antigen
retriex-al to reduce fixation v-ariation (Shi et al. 1991: Ta lor et al.
1994). Tw-enty-eight patients had adequate material from both the
prestudy and the 1"-month biopsies for immunohistochemical
analysis.
Each slide xx-as exaluated for proliferation rate. determined bv
counting, the number ofpositix elv stained epithelial nuclei dixided
by the number of total epithelial nuclei under four consecutiVe
high-pow-er fields (400x). The proliferation rates were determined
by one in'-estigator (CES) on all of the slides from each prestudy
and 12-month biopsy specimens from a total of 28 patients (14
treated. 14 observation: fixve xxith a PIN lesion on the prestudv
biopsy in each group).
Statistical analysis
Standard methods (t-tests and txxo-bx-txx-o table analxysis) were used
for statistical analysis of the data: analx-sis was carried out wxith the
statistical packages EPILOG (Epicenter Softxare. Pasadena. CA.
USA) and SAS (SAS Institute. Cary. NC. USA). Computation of
sianificance levels forthe analy-sis oftxwo-bv-tx o tables was carried
out using Fisher's exact test (Mehta and Patel. 1983). All statistical
si,ofnificance lexels IP-xvalues) quoted are tx-o-sided.
RESULTS
Serum hormones
The mean serum PSA shoxxed a significant and sustained reduc-
tion in the finasteride group but not in the control group (Figure 1):
the maximum effect xas achiexved by the 3-month sample and
remained steady thereafter. There x-as a48%7 reduction in the mean
serum PSA in the finasteride grroup from baseline to 12 months
IP<0.001: Table 1). There xxas no significant chan5e in the
control group (P = 0.44).
The mean serum DHT lexvel decreased 67%7 in the finasteride
group from baseline to 12 months (P < 0.001: Table 1): this effect
xas again achiexed by the 3-month sample. There xxas no signifi-
cant change in the control group (P = 0.12).
Each of the 27 patients in the finasteride group shoxxed a
decrease in PSA and DHT. demonstrating compliance xxith the
medication by all patients.
The mean serum T in the finasteride group increased 21% from
baseline to 12 months (P < 0.001: Table I): this effect was seen by
the time of the 3-month sample. There xxas no significant change
in the control group (P = 0.12 1).
Glandular epitheliumAhyperplastic epithelium
The mean per cent ofglandular tissue present x ithin the prestudy
and the 12-month finasteride group biopsies and control biopsies
x-as similar (Table 2): neither change from pre- to post-studx xxas
statistically significant. and the difference in the change from base-
line to 12 months between the finasteride and control groups x as
also not statistically si-nificant (P = 0.53).
The per cent of tissue demonstrating glandular hyperplasia
showxed a significant decrease in the finasteride-treated group
betwxeen prestudy and 12-month biopsies (P = 0.002: Table 2) but
not in the control group (P = 0.22). Howexer. the decrease in
hyperplastic epithelium was not signiificantlv different betx een the
finasteride and control groups (8.3cl vs 2.9%7. P = 0. 1).
Proliferation rate
The baseline proliferation index for prostate epithelium Aas low in
both groups. but particularly in the control group (0.67 xs 0.95 in
the finasteride group). Although the finasteride group 1"-month
proliferation index increase of0.11 oxer the prestudy wxas less than
the control group increase of 0.36. this difference xxas not statisti-
callv sionificant (P = 0.44).
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Table 3 Effect of finasteride on the prevalence of PINa
Finasteride vs
Variable Finasteride Control control
Number of patients 27 25
PIN in prestudy biopsy 8 5
PIN in 12-month biopsy 8 5
(100°o) (100°o)
No PIN in prestudy biopsy 19 20
PIN in 12-month biopsy 3 6
(16°o) (300o) P= 0.45
aPIN. high-grade prostatic intraepithelial neoplasia.
Table 4 Effect of finasteride on the detection of prostate cancer in men with
and without PINa on prestudy biopsy
Finasteride vs
Variable Finasteride Control control
Number of patients 27 25
Prostate cancer in 8 1
12-month biopsy (300o) (4O0) P= 0.025
PIN in prestudy biopsy 8 5
Prostate cancer in 6 0
12-month biopsy (750o) (0Oo) P= 0.021
No PIN in prestudy biopsy 19 20
Prostate cancer in 2 1
12-month biopsy (11hO) (Sco) P= 0.60
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There A-ere 13 patients (eight in the finasteride group and five in
the control group) with high-grade PIN (moderate or severe. grade
II or III) in the prestudy biopsies (Table 3). All 13 had PIN lesions
in their 12-month biopsies. Three (16%c) of the 19 patients in the
finasteride group w-ho were negative for PIN in their prestudy
biopsy had PIN lesions in their 1 -month biopsy. compared Aith 6
(30%7c) of the 20 such patients in the control group: this difference
Awas not statisticallx significant (P = 0.45).
10
0
month 0 month 1 month 3 month 6 month 12
PSA (ng mrK): observabon arm
Detection of prostate carcinoma at 12-month biopsy
Of the 27 patients treated wxith finasteride. eight (30%7r) had
ex idence of prostate carcinoma in the 12-month biopsy compared
xxith only 1 (4%l) of the 25 control patients (P = 0.025: Table 4).
Patients >-ho had exidence of prostate carcinoma in the 12-month
biopsy were indistinguishable from those wxho did not. based on
baseline PSA lexels (Figure 1).
The presence of PIN in the prestudy biopsies of patients treated
wxith finasteride was significantly associated xxith the detection of
prostate carcinoma in the 12-month biopsy. Ofeight patients in the
finasteride group xho had PIN in the prestudy biopsy. six (75%C)
had detectable prostate carcinoma in the 12-month biopsy. In the
Figure 1 Mean serum PSA levels in finasteride and control patients.
Participants with no prostate cancer found at follow-up study:
-. participants with prostate cancer found at follow-up biopsy
control group of fixe patients w-ith PIN in the prestudy biopsy.
none had detectable prostate carcinoma in the 12-month biopsies.
This difference (six of eight compared with zero of fixve) xas
statistically significant (P = 0.021: Table 4).
There x-as no significant difference in the detection of prostate
carcinoma in the 12-month biopsies of the finasteride and control
cgroups in those patients xxithout PIN in the prestudv biopsy. A total
of 19 and 20 treatment and control group patients. respectivelv. had
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no evidence of PIN in prestudy biopsies; two (11%) and one (5%)
ofthese patients. respectively, had detectable prostate carcinoma in
the 12-month biopsies (P = 0.60; Table 4).
Ofthe nine patients with prostate carcinoma detected in the 12-
month biopsy, seven underwent radical prostatectomy (six from
the treatment group. one from the control group). Five of these
patients had multifocal, bilateral disease with Gleason scores of
6-7; among these, one carcinoma had penetrated through the
prostate capsule and another involved an apical (distal) surgical
margin. Two patients had only small foci of carcinoma. The
prostate from the patient in the observation group showed bilateral
disease. which was confined to the prostate and did not involve the
seminal vesicles. None ofthe patients had lymph node metastases.
DISCUSSION
In an effort to investigate the chemopreventive potential of Sa-
reductase inhibitors, this study was designed to determine the
histopathological effects of fmastende on the peripheral zone of
the prostate ofmen at high risk ofprostate cancer as evidenced by
an elevated serum PSA. The effects offinasteride on serum levels
ofPSA, DHT and T in this trial were consistent with prior reports.
showing significant decreases in PSA and DHT. and an increase in
T. One yearofdaily treatment with finasteride resulted in a modest
decrease in the proportion of hyperplastic glandular epithelium
and a small decrease in the incidence of new PIN lesions, but no
decrease in glandular proliferation rate, and no change in pre-
existing PIN lesions. Fmasteride-treated men in the study had a
significantly increased detection rate of prostate cancer at 1 year.
This excess was largely limited to men with PIN on prestudy
biopsy. This study raises serious questions about the probable
efficacy offmasteride in preventing prostate cancer.
The design of our study differs significandy from that ofthe trial
sponsored by the US National Cancer Institute investigating finas-
teride as apotential prostate cancerchemopreventive agent. Ourtrial
includedonly men withelevated serum PSA; incontrast, the national
trial specifically excludes men with elevated serum PSA. The pres-
ence ofPIN is known to be associated with elevations in serum PSA
(Brawer, 1992). so that the prevalence ofPIN in men enrolled in the
national trial may be lowerthan in ourstudy.
The differential effects of T and DHT on the prostate are well
described; several studies have demonstrated the primary depen-
dence ofthe prostate and male extemal genital organ development
on DHT (Imperato-McGinley et al, 1974; Walsh et al, 1974).
whereas Wolffian duct derivatives (ejaculatory ducts, vas deferens.
seminal vesicles and epididymis) rely primarily on T (Wilson,
1989). Brooks et al (1981) first demonstrated the attenuating effect
of5a-reductase inhibitors on ventral prostate growth. During such
treatment, intaprostatic levels of DHT are decreased, whereas
those of T are increased. Fmasteride (Proscar, MK-906) has been
the most widely studied Sa-reductase inhibitor. Finasteride does
not have any androgenic or other steroid-related properties. In
initial studies it was deternined thatfinasteride at 5 mg day-' is the
optimal dose for maximal symptomatic improvement in men
suffering from BPH (Stoner et al. 1994a). Symptomatic relief is
thought to be due to the 17-30% reduction in prostate volume after
fimasteride treatment lasting 6 months or longer (Gormley et al.
1992; Stoner et al, 1994a: Anderson et al. 1995; Geller. 1995;
Lepor et al. 1996).
The goal of our study was to examine the biological effects of
finasteride on the epithelium of the prostate. and to establish a
model for the study of late-stage efficacy of potential chemo-
preventive agents for prostate carcinoma. We chose men with
elevated serum PSA but no histological evidence of prostate
cancer, as these men are at increased risk for the development of
prostate carcinoma (Keetch et al. 1994). These men also have a
high incidence of high-grade PIN (Brawer. 1992). a histological
precursor ofprostate malignancy. thus making them an interesting
population to study for chemopreventive efficacy. We examined
the histological effects of fmasteride on its principal target.
prostatic glandular epithelium, and on two putative intermediate
markers of prostatic malignancy. glandular proliferation rate
(Preston-Martin et al, 1990) and PIN. High-grade PIN is consid-
ered a premalignant lesion (McNeal and Bostwick. 1986; Brawer.
1992). and has molecular and cellular changes similar to those
seen in prostate cancer (Gould et al. 1996; Salem et al. 1997). Our
hypothesis was that if fmasteride has chemopreventive properties.
it should show effects on prostate epithelial cell growth and. if
effective late in the carcinogenic process. these effects may
include reduction in the incidence of PIN. We were unable to
demonstrate any beneficial effect of finasteride treatment on
glandular proliferation or pre-existing PIN lesions. Moreover. in
patients with pre-existing PIN lesions, treatment with fmasteride
was statistically significantly associated with an increased
incidence ofprostate cancer at 1 year.
That fmasteride did not have tumour inhibitory properties in this
study is not completely surprising. Brooks et al (1991) found that
fmasteride treatment in rats implanted with the rat Dunning
prostate carcinoma cell line. R-3327, failed to influence tumour
growth or histology. Stoner et al (1994b) diagnosed an equal
numberofprostate cancers among patients treated with fmasteride
or placebo for benign prostatic hyperplasia. although pretreatment
biopsies were not obtained. Among men with pre-existing stage II
prostate cancer. Sa-reductase inhibitors are ineffective in reducing
tumour size (Presti et al. 1992).
Why fmasteride treatment resulted in increased cancerdetection
is unclear. It is possible that some ofthe men with cancer detected
in the 12-month biopsy, both in the treatment and observation arm.
had pre-existing occult carcinoma at study entry. As fmasteride
causes a decrease in gland size, this may result in a bias in detec-
tion ofcancer on 12-month biopsy (i.e. a prostate cancer lesion of
a given size may be more likely to be detected by a random biopsy
of a smaller gland). Evidence that this may have occurred is
providedby the observation that two-thirds ofthe cancers detected
were only seen in one ofthe six sextant biopsies. The magnitude of
the bias is somnewhat less than directly proportional to the reduc-
tion in prostatic volume, approximately 19%. This is insufficient
to explain the increased cancer rate in the fmasteride group. The
number of cancers detected in the control group at I year is less
than we anticipated based on historical data, although previous
studies have focussed on men with persistently elevated PSA
levels. The probability is small that the difference in prostate
cancer detected in the treatment vs the control arm is entirely due
to chance.
Several studies have now shown that at increased concentra-
tions, T can stimulate the androgen receptorsimilarly to DHT; thus
androgenic stimulation can occur in the face of reduced DHT
(Grino et al, 1990; Lamb et al, 1992). Although finasteride leads to
much reduced intraprostatic DHT. it also results in substantially
increased intraprostatic T levels (Norman et al. 1993). This obser-
vation combined with recent work demonstrating that. in some
cases. fmasteride might actually stimulate the growth of human
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prostate cancer (Umekita et al, 1996), suggests the possibility that
it may also selectively stimulate PIN.
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